Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding
about
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwideCost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationPersonalizing oral anticoagulant treatment in patients with atrial fibrillation.
P2860
Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding
description
im November 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 22 June 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2012
@uk
name
Increasing CHADS2 scores may a ...... reducing intracranial bleeding
@en
Increasing CHADS2 scores may a ...... reducing intracranial bleeding
@nl
type
label
Increasing CHADS2 scores may a ...... reducing intracranial bleeding
@en
Increasing CHADS2 scores may a ...... reducing intracranial bleeding
@nl
prefLabel
Increasing CHADS2 scores may a ...... reducing intracranial bleeding
@en
Increasing CHADS2 scores may a ...... reducing intracranial bleeding
@nl
P50
P1476
Increasing CHADS₂ scores may a ...... reducing intracranial bleeding
@en
P2093
Giuseppe Giacchi
Valeria Calvi
P304
P356
10.1016/J.IJCARD.2012.06.029
P407
P577
2012-06-22T00:00:00Z